The purpose of this Commentary is to briefly summarize the current knowledge of nephrogenic systemic fibrosis in order to promote better understanding of the complexity of chronic kidney disease and its associated conditions.
evidence that modulation of the immune response is beneficial, suggests that future therapies can be based on this modulation ( Figure 1 ). As continuing research unravels the plethora of mechanisms at play, the number of targets and potential treatment opportunities will increase. Strategies that target each step of the recruitment, activation, and modulation of the inflammatory response are possible. Among the opportunities for salutary intervention in renal I/R injury as highlighted by the study of Sandovici et al. 1 is a strategy that alters the balance between pro-and anti-inflammatory aspects of the response to such injury. A cautionary note must be sounded, as such modulation of the immune system may have unintended and long-term consequences. IL-13 alterations may interfere with the normal clearance of pathogens, since IL-13 potently inhibits the normal T-helper type 1 response to invading pathogens. Nevertheless, as I/R injury is the leading cause of acute renal failure and determinant of the outcome after renal transplantation, every opportunity should be investigated in the pursuit of novel treatments.
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Although recognized as a clinical entity in 1997, nephrogenic systemic fibrosis (NSF) was not reported in the literature until 2000. 1 First termed nephrogenic fibrosing dermopathy, the condition was characterized by extensive cutaneous fibrosis mimicking scleroderma but with notable sparing of the face and neck, absence of scleroderma-associated autoantibodies, and absence of local inflammation (histologically). Over the past 7 years it has become clear that nephrogenic fibrosing dermopathy does not exclusively affect the skin. Evidence of sclerosis has been identified in lungs, heart, liver, and muscles, and therefore the term NSF better describes the systemic nature of the condition. 2 Because of the devastating nature of the disease, in less than one decade it has gone from a state of obscurity to one of common parlance among nephrologists, dermatologists, and radiologists. Notwithstanding, the pathobiology of NSF remains incompletely understood.
Current state
The link to gadolinium-containing contrast agents (GCCAs), first established in 2006, 3 has led several regulatory bodies to issue practice-altering recommendations.
In its communiqué dated 23 May 2007, the United States Food and Drug Administration advises health-care professionals to avoid using GCCAs in persons at risk for the development of NSF, to evaluate patients for renal dysfunction, to not exceed the recommended GCCA dose in product labeling, and to consider prompt hemodialysis after administration of a GCCA. 4 The American College of Radiology has issued a similar recommendation. In this era of increasing attention to patient safety and rapid disclosure of medical error, these recommendations have necessarily emphasized the need for a highly conservative approach to the use of gadolinium.
It is important to maintain an appropriate perspective, understand this condition, and deal with it in a systematic evidence-based manner. In particular we need to ask a series of questions to move the inquiry from phenomenology to epidemiology to pathobiology expeditiously so that we can understand and prevent the occurrence of NSF. With ongoing publication of progressively sophisticated analyses of cases, case series, and databases, we should be able to accomplish this in the near future ( Figure 1 ). In a manner akin to that of the recent recognition, and subsequent diminution, of the incidence and severity of erythropoietin-associated pure red-cell aplasia, the nephrology community again has a unique opportunity to understand and prevent a rare condition. We must hypothesize what key factors create the 'perfect storm' from which the disease phenotype co mmentar y emerges. Thus, we must ask and answer a series of questions: why now, why this patient group, and what we can do differently to avoid further harm. Importantly, perhaps this condition will help to draw attention to the uniqueness of the chronic kidney disease population with respect to handling of any substance, and caution all as to the need for thorough investigations prior to widespread use.
The true denominator
We know that in 2006, 26.9 million magnetic resonance imaging scans were performed in the United States, and over 200 million were performed worldwide. 5 Since 2000, more than 215 discrete cases of NSF have been described in the literature. 6 Thus, using the true denominator, this condition is extraordinarily rare. Nonetheless, the incidence in those with markedly reduced kidney function is substantially higher, which has alerted us to the unique pathophysiology of this condition.
Patients with the condition are on dialysis, have hepatorenal syndrome, or have acute kidney injury and require dialysis. Interestingly, it appears that the presence of mild acidosis may be an important factor in some cases. 3 Ongoing case reports have also associated NSF with exposure to erthropoiesis stimulating agents (ESAs), angiotensin-converting enzyme inhibitors, and recent vascular procedures. 7 However, considering the widespread use of ESAs and angiotensin-converting enzyme inhibitors and the large number of vascular procedures undertaken, the number of cases of NSF is, again, vanishingly small. Furthermore, the majority of cases have been linked to two agents: gadodiamide and gadopentate. 5 They have specific characteristics that differentiate them from other gadolinium compounds (see below).
Gadolinium has now been identified in the skin samples of patients with NSF. 8, 9 Given the large number of dialysis patients, a high population prevalence of estimated glomerular filtration rate less than 30 ml/min, and the liberal use of gadolinium, what are the unique features that lead to the occurrence of NSF in such a limited number of individuals? This remains the question to be answered in future studies.
Pathobiology and chemistry
Gadolinium (atomic number 64, average atomic weight 157.25 g/mol) is a member of the lanthanide series. Ionized gadolinium, which exists in an oxidation state of 3+, is highly toxic, impairing calcium channel function with documented cardiovascular and neurological toxicity. 5 This toxicity has been attributed to the comparable ionic radii of Ca 2+ and Gd 3+ , 10 which are, respectively, 112 pm and 105 pm (for a coordination number of 8). 11 Therefore, for safe use in humans, Gd 3+ is chelated, which confers water solubility and decreases the toxicity about 30-fold in animal studies. 12 Interestingly, not all gadolinium chelates are created equal. There are two structural classes, referred to as 'linear' and 'macrocyclic. ' Both types of chelates form nine-coordinate complexes with the solvent (water) as one of the ligands, but the macrocyclic compounds coordinate Gd 3+ in a preformed cavity. 13 Linear chelates have been observed to have lower thermodynamic stability, as recently reviewed. 14 Of the five Food and Drug Administration-approved chelates, the linear chelate gadodiamidediethylene triamine pentaacetic acid (DTPA) (Omniscan) is the most frequently associated with NSF. 5 It also has the largest dissociation constant and, accordingly, the shortest half-life of its coordination complex. 14 Interestingly, gadodiamide-DTPA is formulated with 12 mg/ml of excess ligand, presumably to decrease the probability of free Gd 3+ forming. 7 Gadopentate-DTPA, the complex implicated in NSF with the second greatest frequency, 5 shares the features of linear structure and lower thermodynamic stability with gadodiamide-DTPA. 14 Therefore, the structure of the coordinating ligand and the associated lowering in the thermodynamic stability of the coordination complex appear to make linear chelates more susceptible to the transmetalation process, 14 which underpins the pathogenesis of NSF.
However, it should be emphasized that patient factors certainly also play a role in Gd 3+ exposure. In people with normal renal function, gadolinium chelates have a half-life of 1.3 hours. However, with reducing glomerular filtration rate, this clearance time is increased, and in dialysis patients, GCCA half-life is extended to between 30 and 120 hours. 7 Thus, in those with chronic kidney disease, the slow clearance of GCCA provides a protracted time period in which transmetalation may occur. This may be why NSF affects those with low glomerular filtration rates with such predominance.
Naturally, the transmetalation process is facilitated by those ions that substitute for Gd 3+ in the metal complex. In vivo, the proposed ions have been those of calcium, zinc, iron, copper, and aluminum. 7 Transmetalation occurs more quickly in acidic conditions. 14 Thus it is conceivable that in the clinical context of chronic kidney disease, where patients are frequently acidotic and regularly receive boluses of intravenous iron products, the transmetalation process might be facilitated.
The study by Swaminathan et al. 15 (this issue) extends observations previously made regarding gadolinium tissue deposition and the association of gadoliniuminduced iron mobilization and transferrin oversaturation. 16 The authors hypothesized that the mobilization of free iron may have furthered the process of transmetalation, leading to deposition of free gadolinium and iron in tissues affected by NSF. 16 The subsequent inflammation, oxidative stress, and tissue injury induced by this deposition may lead to perpetuation of the NSF process. Furthermore, the authors are able to demonstrate staining of metals in tissue samples to corroborate this hypothesis.
The retrospective analysis of 32 cases of NSF identified at their institution describes a high mortality, due to either cardiovascular causes or sepsis. 15 Autopsy results of three patients are presented and are compared with those of normal controls. Gadolinium and iron were isolated in skin and in the heart, aorta, and other organs. Furthermore, coronary artery staining revealed the presence of CD34 + fibroblasts, the same cells that are upregulated in sclerotic areas. The controls did not have any of these findings, but note that they were not on dialysis and did not have exposure to GCCA. If multisystem deposition of gadolinium elicits a local inflammatory response leading to fibrosis not only of skin but of organs and vasculature, it may be that GCCA accelerates cardiovascular mortality in an already susceptible population. The specific compounds used, in combination with an internal milieu (acidosis, presence of iron in excess quantities, and so on), may have created a unique pathobiological state that leads to NSF.
Epidemiology and future research methods
Since the advisory warnings, and the reduction or cessation of use of gadodiamide in susceptible populations, the incidence appears to be reduced. Is this because fewer people are undergoing magnetic resonance imaging testing if they are in a high-risk category, or is it because those that do have been more carefully evaluated, the compound changed, and/ or dialysis instituted quickly?
The creation and maintenance of international registries, with the capacity to collect key clinical information as well as biological samples in patients both affected and unaffected but with similar exposures, is imperative if we are to understand this rare condition in a time of quickly changing practices. The current NSF Registry in Boston is an example of this kind of initiative (http://www.icnfdr. org), though more comprehensive investigation of all exposed, not simply those with the condition, could be undertaken.
Ideally 
Summary
Nephrology patients have a multiplicity of conditions that contribute to morbidity and mortality. In addition, they require ongoing evaluation and interventions and treatments for specific conditions. They are unique in that their internal milieu is drastically altered, they are exposed to multiple medications, oxidative stresses, and non-natural materials (catheters, dialyzers), and their ability to excrete ingested or infused substances is limited. Even those therapies that we believe to be innocuous, or helpful need to be studied carefully in specific situations known to affect chronic kidney disease patients. The story of gadolinium-induced NSF is another example of a rare but devastating phenomenon occurring in small numbers of patients, but at an extraordinary rate in a specific population. This is yet another opportunity to better understand the interaction of internal and external environment, complex chemical reactions, and the influence of genotype on disease expression.
The gadolinium story as it relates to NSF will continue to unfold. More extensive understanding of the processes and related pathobiology will emerge. As an international nephrology community, we need to facilitate the collection of data and the development of clinical and biological registries, and to support better understanding of rare conditions.
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